Middle East and Africa Monoclonal Antibodies Market is expected to reach US$ 5,741.1 Million by 2028

Published Date: 05 Apr 2022

Human Segment has the Largest Share of Source in the Middle East & Africa Monoclonal Antibodies Market during 2021–2028

According to our latest study on “Middle East & Africa Monoclonal Antibodies Market Forecast to 2028 – COVID-19 Impact and Analysis – by Source, Production Method, Indication, Application, and End User,” the market is projected to reach US$ 5,741.1 million by 2028 from US$ 3,198.9 million in 2021; it is expected to grow at a CAGR of 8.7% from 2021 to 2028. The report highlights trends prevailing in the market, and the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the rising prevalence of cancer and other chronic diseases, mABs uptake proves to be effective during pandemic outbreaks. However, low awareness, accessibility, and high cost is expected to restrict the market growth during the forecast period.

The demand for monoclonal antibody-based products in Saudi Arabia have a high success rate in clinical development and is reported that the probability of FDA approvals for mABs in Phase 1 of development in ~14.1% that is almost twice the approval rate of small molecule drugs (~7.6%). On the other hand, the IAVI report states that with the onset of pandemic worldwide many biopharmaceutical companies sell mABs based products at affordable prices. For example, in South Africa, Roche sells its breast cancer mAB "trastuzumab" as both Herceptin the original brand as a second brand called "Hercelon". Apart from that, as availability of these mABs is limited, various pharmaceutical companies are conducting clinical trials in middle-income counties. For example, Merck is conducting clinical trials in several middle-income countries such as South Africa, Colombia, and Malaysia. Such aforementioned factors have positive influence in the regional market thereby witnessing high adoption of monoclonal antibody in Middle East and Africa region amid COVID-19 pandemic.

Based on source, the Monoclonal Antibodies (mAbs) market is segmented into human, humanized, chimeric, and murine. In 2020, the human segment accounted for the highest share, moreover the same segment is expected to grow in the forecast period.

Novartis AG, Pfizer Inc., GlaxoSmithKline plc., Amgen Inc., DAIICHI SANKYO COMPANY, LIMITED, F. Hoffmann-La Roche Ltd., AstraZeneca, Bayer AG, and Bristol-Myers Squibb Company are among the leading companies in the Middle East & Africa monoclonal antibodies market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market.

The market for monoclonal antibodies market is segmented into source, production method, indication, application, and end user. Based on source, the Middle East & Africa monoclonal antibodies market is segmented into human, humanized, chimeric, murine. Based on production method, the monoclonal antibodies market is segmented into in-vitro, in-vivo. Based on indication, the monoclonal antibodies market is segmented into cancer, autoimmune diseases, infectious diseases, inflammatory diseases, microbial diseases, others. Based on application, the monoclonal antibodies market is segmented into therapeutic applications, diagnostic applications, research applications. Based on end user, the monoclonal antibodies market is segmented into hospitals, research institutes, others. Geographically, the monoclonal antibodies market is segmented into Middle East & Africa (UAE, Saudi Arabia, South Africa, Rest of Middle East & Africa).

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com

Download Free PDF Brochure